Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Hemophilia A
Interventions: BAX 888; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 5 more

Conditions: Plantar Fasciitis
Interventions: platelet rich plasma, corticosteroid injection; Biological · Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Bernadino, California

Conditions: Stroke, Aphasia, Reading Disorder
Interventions: Phono-Motor Therapy, Aerobic Exercise Training (AET), Stretching; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Cystic Fibrosis
Interventions: PTI-428, Placebo; Drug
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 20
States / cities: Stanford, California • Altamonte Springs, Florida • Gainesville, Florida + 16 more

Conditions: Psoriasis, Obesity, Cardiovascular Risk, Inflammation
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: Up to 18 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Stress Urinary Incontinence
Interventions: Mid-urethral sling; Procedure
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 190 participants
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Skokie, Illinois

Conditions: Hearing Loss
Interventions: DEEPSONIC™ Deep Sound Optimized Neural Integrated Chip Artificial intelligence-based noise reduction; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 110 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Palbociclib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Autoimmune Hepatitis
Interventions: mindfulness based stress reduction; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hiv
Interventions: Mobile Game, Mobile Application; Other
Lead sponsor: George Washington University; Other
Eligibility: 13 Years to 24 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Coronary Artery Disease, High-risk Percutaneous Coronary Intervention, Interventional Cardiology
Interventions: Supira System; Device
Lead sponsor: Supira Medical; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Sacramento, California • Atlanta, Georgia • New York, New York + 1 more

Conditions: Epilepsy
Interventions: Discontinue antiseizure medications; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse
Interventions: Idasanutlin, Obinutuzumab, Venetoclax, Rituximab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Louisville, Kentucky + 4 more

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions: Ara-C, Mitoxantrone, Etoposide; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 10 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions: docetaxel, thalidomide; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older · Male only
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Knee Pain Chronic, Osteo Arthritis Knee
Interventions: HB-adMSC; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Obesity
Interventions: PF-06882961, Rosuvastatin, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo (semaglutide), Liraglutide, Placebo (liraglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Fullerton, California • Huntington Beach, California + 15 more

Conditions: Ulcerative Colitis
Interventions: SPH3127, Placebo; Drug
Lead sponsor: Shanghai Pharma Biotherapeutics USA Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 16
States / cities: Huntsville, Alabama • Los Angeles, California • Mission Hills, California + 13 more

Conditions: Caries
Interventions: verbal education, verbal education, visual aids, and motivational interviewing; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Up to 6 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Breast Cancer
Interventions: Placebo, Lidocaine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Heart Failure, Congestive, Chronic Heart Failure, Depression
Interventions: Sertraline, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 45 Years and older
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Perioperative Care, EEG Power Spectra, Delirium - Postoperative
Interventions: Standard of Care EEG-Guided Emergence, Extended EEG Emergence Trajectory; Procedure
Lead sponsor: Harrison Shong-Wen Chow; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Hyperpolarized Xe129; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Search by objective public record fields.

A Study of BAX 888 in Male Adults With Severe Hemophilia A

Treatment of Plantar Fasciitis With Platelet Rich Plasma

Combined Exercise and Targeted Therapy for Post-Stroke Reading Deficits

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis

Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis

The Effect of Mid-urethral Sling on the Urethral Dynamic Shape and Motion

AI Noise Reduction in Phonak Hearing Aids

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

Mindfulness - Based Stress Reduction and the Relationship on Inflammation in Autoimmune Hepatitis

Efficacy Trial of Life Simulation Game to Routinize Adolescent HIV Testing

Early Feasibility Study of the Supira System in Patients Undergoing HRPCI

Outcomes After Planned Discontinuation of AntiSeizure Medication

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

Individual Patient Expanded Access IND of Autologous HB-adMSCS for the Treatment of Bilateral Knee Pain.

Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis

A Strategy to Prevent the Recurrence of Dental Disease in Children Receiving Dental Treatment With General Anesthesia

IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery:

Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure

Extended Emergence Strategy on Post-Anesthesia Care Unit Events After Outpatient Orthopedic Surgery

Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension